Missouri tax holiday offers savings on energy-efficient appliances
From April 19-25, state sales tax will be waived on qualifying ENERGY STAR-certified appliances.
Download WDAF+ for Roku, Fire TV, Apple TV
This certification can result in better performance and long-term energy savings because it shows that a product has been independently confirmed to meet strict standards.
'All Missouri cities, counties, and districts participate in the appliance sales tax holiday,' said Missouri's Director of Revenue Trish Vincent.
'This event not only encourages Missourians to be energy minded but it also contributes to increased revenues for local businesses across the state who sell these appliances.'
Missouri news: Headlines from St. Louis, Jefferson City and across the Show-Me State
The first $1,500 of each appliance purchased is exempt from state sales tax, including air conditioners, refrigerators with the Energy Star certification, clothes washers, dryers, dishwashers, and more.
Click here for a full list of items that qualify for the holiday.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Salarius: Q2 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Salarius Pharmaceuticals, Inc. (SLRX) on Tuesday reported a loss of $958,000 in its second quarter. The Houston-based company said it had a loss of 45 cents per share. _____
Business Wire
2 hours ago
- Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablation Submitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months. Treated 40 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study in Europe. Endocardial Catheter AF Ablation Submitted FDA IDE application, including the pivotal study protocol, and remain on track to commence the IDE pivotal study in the next few months. Observed improved procedure times since last presented at the Heart Rhythm Society 2025 Meeting in April. Treated over 140 total patients with the nsPFA 360° catheter to date as part of the multi-center, first-in-human AF study in Europe. 'We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs,' said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. 'I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360° catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe. These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease, AF and additional diseases in the future.' Second Quarter 2025 Financial Results Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended June 30, 2025, were $20.3 million, an increase of $8.5 million compared to $11.7 million in the prior year period. The increase was primarily driven by administrative expenses related to the expanding organization to support advancement of the nsPFA device clinical trials and commercialization, and non-cash stock-based compensation and other compensation. Non-GAAP costs and expenses for the three months ended June 30, 2025, were $14.8 million, an increase of $5.4 million compared to $9.4 million in the prior year period. GAAP net loss for the three months ended June 30, 2025 was ($19.2) million compared to ($11.4) million for the three months ended June 30, 2024. Non-GAAP net loss for the three months ended June 30, 2025 was ($13.7) million compared to ($9.0) million for the three months ended June 30, 2024. Cash and cash equivalents totaled $106.3 million as of June 30, 2025, compared to $26.2 million as of June 30, 2024 and $119.3 million as of March 31, 2025. Cash used in operating activities in the second quarter of 2025 totaled $12.8 million, compared to $8.4 million used in the same period in the prior year, and $13.5 million used in the first quarter of 2025. Reconciliations of GAAP to Non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading 'Non-GAAP Financial Measures.' Webcast and Conference Call Information Pulse Biosciences' management will host a conference call today, August 12, 2025, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available at About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Non-GAAP Financial Measures In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, restructuring, severance, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization, restructuring costs, severance expense and legal settlement expenses. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's future commercialization and product development efforts and whether those efforts will be successful, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nsPFA 360° Cardiac Catheter System, the nsPFA Cardiac Surgical System, and the nsPFA Percutaneous Electrode System, and statements concerning the Company's future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as 'may,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Product revenues $ — $ — $ — $ — Total revenues — — — — Cost and expenses: Research and development 12,088 7,230 22,401 13,971 General and administrative 8,187 4,496 15,918 8,370 Total cost and expenses 20,275 11,726 38,319 22,341 Loss from operations (20,275 ) (11,726 ) (38,319 ) (22,341 ) Other income: Interest income, net 1,107 343 2,356 821 Total other income 1,107 343 2,356 821 Net loss (19,168 ) (11,383 ) (35,963 ) (21,520 ) Comprehensive loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Net loss per share: Basic and diluted net loss per share $ (0.28 ) $ (0.20 ) $ (0.54 ) $ (0.38 ) Weighted average shares used to compute net loss per common share — basic and diluted 67,276 57,180 67,201 57,152 Expand Reconciliation of GAAP to Non-GAAP Financial Measures The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: (In thousands) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Reconciliation of GAAP to non-GAAP Research and development: GAAP Research and development $ 12,088 $ 7,230 $ 22,401 $ 13,971 Less: Stock-based compensation expense (2,335 ) (1,001 ) (5,097 ) (1,950 ) Less: Depreciation and amortization (44 ) (52 ) (90 ) (105 ) Non-GAAP Research and development $ 9,709 $ 6,177 $ 17,214 $ 11,916 Reconciliation of GAAP to non-GAAP General and administrative: GAAP General and administrative $ 8,187 $ 4,496 $ 15,918 $ 8,370 Less: Stock-based compensation expense (2,854 ) (1,051 ) (5,773 ) (1,861 ) Less: Depreciation and amortization (229 ) (246 ) (466 ) (492 ) Add: Legal settlement — — 590 — Non-GAAP General and administrative $ 5,104 $ 3,199 $ 10,269 $ 6,017 Reconciliation of GAAP to non-GAAP Cost and expenses: GAAP Cost and expenses $ 20,275 $ 11,726 $ 38,319 $ 22,341 Less: Stock-based compensation expense (5,189 ) (2,052 ) (10,870 ) (3,811 ) Less: Depreciation and amortization (273 ) (298 ) (556 ) (597 ) Add: Legal settlement — — 590 — Non-GAAP Cost and expenses $ 14,813 $ 9,376 $ 27,483 $ 17,933 Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Add: Stock-based compensation expense 5,189 2,052 10,870 3,811 Add: Depreciation and amortization 273 298 556 597 Less: Legal settlement — — (590 ) — Non-GAAP Net loss $ (13,706 ) $ (9,033 ) $ (25,127 ) $ (17,112 ) Expand
Business Wire
2 hours ago
- Business Wire
KashKick is the 22nd-Fastest Growing US Company on Inc Magazine's Prestigious Annual 5000 List for 2025
TAMPA, Fla.--(BUSINESS WIRE)--KashKick, the premium online gaming, surveys, shopping, and brand discovery platform that converts screen time into pocket money for its 3.5 million users, today announced their prestigious 22nd place ranking on Inc. Magazine's 2025 list of the United States' 5000 fastest-growing private companies by revenue, the Inc. 5000. This is the second consecutive year the company has placed. The Inc. Class of 2025 represents a cohort of resilient and growth-minded teams whose dedication has merited steady but robust increases in revenue amidst mounting inflationary pressures. KashKick's product-oriented approach to rewarding users for their time and attention resulted in revenue growth of 8,151% between 2021 and 2024. "We've always believed that rewarding our users for their time while delivering real value to our brand partners creates a sustainable win-win ecosystem. Being recognized on the Inc. 5000 again validates that our approach is making a meaningful impact," said Vishal Mahtani, Co-Founder and Chairman of the Board. Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent — not subsidiaries or divisions of other companies — as of December 31, 2024. Inc. 5000 at a glance: Inc. 5000 alumni include: Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle and Patagonia. The minimum revenue required for 2021 was $100,000; the minimum for 2024 was $2 million. Growth rates used to determine company rankings were calculated to four decimal places. For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to All 5000 companies are featured on starting Tuesday, August 12. About Inc. Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.'s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit About KashKick and Besitos Established in 2017 by industry veterans Vishal Mahtani and Jacob Shemesh, Besitos Corporation, LLC (beh-see-tohs) is a Tampa, Florida-based consumer products company dedicated to rewarding users for their time and attention. Recognized on the Inc 5000 list for two consecutive years, ranking #11 in 2024 and #22 in 2025, the company has demonstrated exceptional growth in the competitive digital rewards space. The company's flagship product, KashKick, is a gamified rewards marketplace that empowers users to earn real money online by completing simple digital tasks—no points, just cash. Built for the next generation of earners, KashKick bridges the gap between brand discovery and consumer empowerment, giving users control over how they engage and earn. Besitos currently comprises two key products: KashKick and Besitos Marketplace. Leveraging an API and microservices architecture, Besitos enables partners to monetize their brands and enhance consumer engagement through comprehensive rewards and loyalty programs. For more information, visit and
